Dr Lal Pathlabs Ltd

₹ 2,464 -0.87%
07 Dec - close price
About

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]

Key Points

Infrastructure
The company operates an established network of 216 laboratories, 3095 Patient Service Centres & ~7,000 Pick-up Units. [1] Out of its total labs, 33 labs are also NABL accredited. [2] Its flagship labs include National Reference Lab at Delhi and Regional Reference Lab at Kolkata. [3]

  • Market Cap 20,542 Cr.
  • Current Price 2,464
  • High / Low 3,893 / 1,805
  • Stock P/E 82.8
  • Book Value 186
  • Dividend Yield 0.49 %
  • ROCE 29.4 %
  • ROE 25.1 %
  • Face Value 10.0

Pros

  • Company has been maintaining a healthy dividend payout of 43.5%
  • Company's median sales growth is 18.2% of last 10 years

Cons

  • Stock is trading at 13.2 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Healthcare

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
366 328 302 266 432 452 431 607 498 497 486 503 534
257 246 244 218 305 314 309 418 357 388 364 385 390
Operating Profit 109 82 57 48 127 139 122 189 142 109 121 118 144
OPM % 30% 25% 19% 18% 29% 31% 28% 31% 28% 22% 25% 23% 27%
15 14 12 11 13 14 14 14 14 12 12 8 9
Interest 4 4 4 4 4 4 4 5 5 9 12 8 11
Depreciation 18 19 20 18 20 20 20 19 20 31 38 36 39
Profit before tax 102 73 45 38 117 129 111 179 131 82 84 81 103
Tax % 21% 25% 28% 25% 25% 26% 23% 25% 26% 29% 26% 28% 30%
Net Profit 81 55 33 28 87 96 85 134 96 58 62 58 72
EPS in Rs 9.66 6.49 3.90 3.41 10.23 11.34 10.01 15.74 11.40 6.88 7.35 6.92 8.60
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
237 342 452 558 660 791 912 1,057 1,203 1,330 1,581 2,087 2,019
181 256 354 419 504 582 675 793 910 987 1,145 1,526 1,527
Operating Profit 57 87 98 139 156 210 238 264 294 344 436 561 492
OPM % 24% 25% 22% 25% 24% 26% 26% 25% 24% 26% 28% 27% 24%
2 2 3 8 12 20 27 31 46 55 51 52 41
Interest 1 3 0 0 0 0 1 1 1 15 16 30 40
Depreciation 14 20 20 27 28 28 28 33 38 73 77 108 143
Profit before tax 45 66 80 119 140 201 237 261 301 310 394 475 349
Tax % 34% 32% 31% 33% 31% 34% 34% 34% 33% 27% 25% 26%
Net Profit 29 45 55 80 96 133 156 172 200 228 296 350 251
EPS in Rs 858.49 1,333.04 1,643.22 148.27 17.51 15.99 18.61 20.49 23.90 27.11 34.99 41.37 29.75
Dividend Payout % 19% 19% 9% 7% 9% 15% 16% 22% 25% 44% 57% 29%
Compounded Sales Growth
10 Years: 20%
5 Years: 18%
3 Years: 20%
TTM: 2%
Compounded Profit Growth
10 Years: 23%
5 Years: 17%
3 Years: 20%
TTM: -39%
Stock Price CAGR
10 Years: %
5 Years: 23%
3 Years: 15%
1 Year: -31%
Return on Equity
10 Years: 26%
5 Years: 24%
3 Years: 24%
Last Year: 25%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
5 5 5 80 81 83 83 83 83 83 83 83 83
Reserves 88 111 157 151 260 424 512 734 890 974 1,162 1,425 1,466
20 0 0 1 0 0 0 0 0 0 150 532 285
59 63 108 146 161 119 95 98 117 317 265 309 467
Total Liabilities 169 177 269 352 475 625 690 916 1,091 1,374 1,661 2,349 2,302
112 108 127 140 150 166 152 208 209 413 447 1,375 1,353
CWIP 0 6 1 0 1 4 18 10 3 11 10 15 7
Investments 1 5 55 9 38 64 106 145 185 164 59 65 124
56 58 87 203 286 391 414 554 694 786 1,144 893 818
Total Assets 169 177 269 352 475 625 690 916 1,091 1,374 1,661 2,349 2,302

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
42 68 88 98 122 159 171 197 219 284 398 447
-19 -26 -64 -89 -113 -163 -137 -172 -100 -26 -212 -449
-22 -38 -15 -10 -1 0 -32 13 -55 -190 -139 136
Net Cash Flow 1 4 9 -2 8 -5 2 37 64 67 48 134

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 15 15 16 16 17 17 17 14 16 14 15 15
Inventory Days 37 31 33 44 40 70 39 38
Days Payable 90 89 97 106 111 144 132 107
Cash Conversion Cycle 15 15 16 16 -35 -42 -47 -47 -55 -60 -78 -54
Working Capital Days -43 -27 -39 -26 -9 27 19 17 0 -19 -17 -14
ROCE % 60% 58% 61% 49% 47% 43% 37% 34% 32% 33% 29%

Shareholding Pattern

Numbers in percentages

35 recently
Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
56.81 56.77 56.32 55.23 55.23 55.23 55.23 55.23 55.23 55.23 55.05 55.04
20.34 20.01 19.95 22.42 24.37 26.01 26.42 26.82 25.45 23.44 22.37 23.26
10.07 9.94 10.28 9.62 8.84 7.52 6.54 5.73 6.57 6.83 6.52 6.27
11.69 12.23 12.42 11.77 10.65 10.37 10.96 11.42 12.01 13.80 15.46 14.84
1.09 1.04 1.03 0.96 0.91 0.87 0.85 0.80 0.74 0.70 0.60 0.58

* The XBRL reporting format changed from Sep'2022 onwards. The new format added details about banks and foreign portfolio investors. These were not available earlier.
The sudden increase in FII or DII might be because of these changes.

Please click on the line-items to see the names of individual entities.

Documents

Concalls